In addition, PD-1/PD-L1 immunocheckpoint inhibitors acting as immunomodulatory drugs can significantly enhance the natural defense of the immune system against cancers, while inevitably leading to some immune-related adverse events, the erroneous stimulation of the immune system leads to immune injuries to the normal tissues of the body (14). Here, PDCD1 is linked to cancer.